hydroxychloroquine has been researched along with Bright Disease in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 7.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with known immunomodulatory, anti-inflammatory, and autophagy inhibitory effects; it is recognized in the treatment of autoimmune diseases such as systemic lupus erythematosus." | 5.91 | Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. ( Inoue, H; Kinoshita, A; Koji, T; Mukae, H; Nishino, T; Obata, Y; Torigoe, K; Torigoe, M, 2023) |
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 3.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| " Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy." | 3.66 | Membranous nephropathy in rheumatoid arthritis. ( Figueroa, JE; Waxman, J, 1982) |
| "The authors report their comparative experience of the treatment of proliferative lupus glomerulonephritis using prednisone (16 patients) or the indomethacin-hydroxychloroquine association (12 patients)." | 3.65 | [Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids]. ( Conte, JJ; Fournie, GJ; Mignon-Conte, MA, 1975) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with known immunomodulatory, anti-inflammatory, and autophagy inhibitory effects; it is recognized in the treatment of autoimmune diseases such as systemic lupus erythematosus." | 1.91 | Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. ( Inoue, H; Kinoshita, A; Koji, T; Mukae, H; Nishino, T; Obata, Y; Torigoe, K; Torigoe, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Torigoe, M | 1 |
| Obata, Y | 1 |
| Inoue, H | 1 |
| Torigoe, K | 1 |
| Kinoshita, A | 1 |
| Koji, T | 1 |
| Mukae, H | 1 |
| Nishino, T | 1 |
| Awdishu, L | 1 |
| Joy, MS | 1 |
| Pons-Estel, GJ | 1 |
| Alarcón, GS | 1 |
| McGwin, G | 1 |
| Danila, MI | 1 |
| Zhang, J | 1 |
| Bastian, HM | 1 |
| Reveille, JD | 1 |
| Vilá, LM | 1 |
| Figueroa, JE | 1 |
| Waxman, J | 1 |
| Conte, JJ | 1 |
| Mignon-Conte, MA | 1 |
| Fournie, GJ | 1 |
| Muirden, KD | 1 |
| Lloyd, DD | 1 |
| Balfe, JW | 1 |
| Barkin, M | 1 |
| Gelfand, EW | 1 |
2 reviews available for hydroxychloroquine and Bright Disease
| Article | Year |
|---|---|
Role of Pharmacogenomics in Kidney Disease and Injury.
Topics: Acute Kidney Injury; Azathioprine; Calcineurin Inhibitors; Cisplatin; Cyclophosphamide; Cytochrome P | 2016 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
1 trial available for hydroxychloroquine and Bright Disease
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
5 other studies available for hydroxychloroquine and Bright Disease
| Article | Year |
|---|---|
Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling.
Topics: Animals; Anti-Inflammatory Agents; Glomerulonephritis; Hydroxychloroquine; Male; Nephritis; p38 Mito | 2023 |
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.
Topics: Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Disease Progression; Female; | 2009 |
Membranous nephropathy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Glomerulonephritis; Humans; Hydroxychloroquine; Kidney Glomerulus; Mal | 1982 |
[Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids].
Topics: Adolescent; Adult; Antibodies; Complement System Proteins; Drug Synergism; Drug Therapy, Combination | 1975 |
Systemic lupus erythematosus with signs of retroperitoneal fibrosis.
Topics: Adolescent; Beta-Globulins; Complement System Proteins; Cyclophosphamide; Female; Glomerulonephritis | 1974 |